Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/3/2024 | $24.00 | Buy | Stifel |
| 1/5/2024 | $23.00 → $26.00 | Buy | Needham |
| 8/9/2023 | $28.00 | Buy | H.C. Wainwright |
| 5/11/2023 | In-line → Outperform | Evercore ISI | |
| 3/13/2023 | $21.00 | Buy | Craig Hallum |
| 10/21/2022 | $16.00 | Buy | Jefferies |
| 5/6/2022 | Outperform → In-line | Evercore ISI |
10-Q - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)
SCHEDULE 13G/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
Stifel initiated coverage of Phathom Pharmaceuticals with a rating of Buy and set a new price target of $24.00
Needham reiterated coverage of Phathom Pharmaceuticals with a rating of Buy and set a new price target of $26.00 from $23.00 previously
H.C. Wainwright initiated coverage of Phathom Pharmaceuticals with a rating of Buy and set a new price target of $28.00
Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $28 price target.
Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly increaseOver 143,000 prescriptions filled for VOQUEZNA® (vonoprazan) products, launch to date, a 138% increase since last quarterly reportCommercial access for VOQUEZNA tablets expanded, now covering over 80% of U.S. commercial livesManagement to host conference call today, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported fin
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December: Guggenheim's Inaugural Healthcare Innovation Conference in Boston, MADate: Tuesday, November 12, 2024Live Webcast: 9:30 am ETManagement to participate in one-on-one meetings throughout the conference Stifel 2024 Healthcare Conference in New York, NYDate: Monday, November 18, 2024Live Webcast: 1:15 pm ETManagement to participate
Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A re
SC 13G - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)
SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)
SC 13D/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)
4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)
Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination
Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer
Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly increaseOver 143,000 prescriptions filled for VOQUEZNA® (vonoprazan) products, launch to date, a 138% increase since last quarterly reportCommercial access for VOQUEZNA tablets expanded, now covering over 80% of U.S. commercial livesManagement to host conference call today, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported fin
Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A re
Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter 2024 compared to $1.9 million in the first quarter 2024, greater than a 280% increaseVOQUEZNA (vonoprazan) tablets 10mg now FDA-approved and available to treat heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (GERD) in adults – unlocking the entire GERD market of over 22 million diagnosed and annually treated patientsExpansion of commercial coverage for VOQUEZNA tablets now includes over 116 million U.S. lives, an estimated 77% of total U.S. commercial livesManagement to
Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour DUBLIN and OXFORD, England, April 22, 2024 /PRNewswire/ -- SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m Series B financing. The financing was co-led by Forbion, HealthCap and new investor Bioqube Ventures. The proceeds will be used to generate registrational Phase 3 clinical and CMC data for emactuzumab, SynOx's potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the tr
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to an additional $40 million under revenue interest financing agreement; total financing potentially available increased to $300 million Commercial launches in H. pylori, and Erosive Esophagitis (EE), if approved, anticipated in Q1 2023 FLORHAM PARK, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the thir
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and Chief Executive Officer of Frazier Lifesciences Acquisition Corporation (NASDAQ:FLAC). In addition to those leadership roles, he